Future prospects for cancer immunotherapy - Strategies for ineffective cancers

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer immunotherapy has gained significant attention following the 2018 Nobel Prize, revolutionizing treatment with immune checkpoint inhibitors (ICIs).
• ICIs offer distinct mechanisms from chemotherapy, leading to tumor shrinkage and long-term survival, significantly impacting cancer care.
• Despite advancements, the efficacy of ICIs as monotherapy remains limited, observed in only 10-30% of patients.

Purpose of the Study:

• To review the future prospects of cancer immunotherapy, focusing on strategies for patients with ineffective responses.
• To discuss the development and potential of combined immunotherapies and Chimeric Antigen Receptor (CAR) T-cell therapy.

Main Methods:

• Review of current literature and clinical trial data on cancer immunotherapy.
• Analysis of the efficacy and limitations of existing immunotherapeutic approaches.
• Exploration of novel combination strategies and emerging therapies like CAR T-cell therapy.

Main Results:

• Over 2,500 clinical trials are investigating combinations with ICIs to enhance therapeutic efficacy.
• Chimeric Antigen Receptor (CAR) gene transfer T-cell therapy has achieved approval for B-cell hematopoietic tumors.
• Monotherapy with ICIs demonstrates response rates between 10% and 30%.

Conclusions:

• Combined cancer immunotherapy approaches are crucial for improving treatment outcomes.
• CAR T-cell therapy represents a significant advancement, particularly for hematological malignancies.
• Future research should focus on developing effective strategies for patients who do not respond to current immunotherapies.